Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 15;13:823132. doi: 10.3389/fphar.2022.823132

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Blanton, McHann, De Selle, Dancel, Redondo, Molehin, German, Trasti, Pruitt, Castro-Piedras and Guindon.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Increase in ovarian (OVCAR-5) cancer ectopic xenograft tumor growth following chronic daily administration of JWH-133 (1 mg/kg) relative to vehicle group in immunocompromised SCID-SHO female mice. JWH-133 (1 mg/kg i.p.) chronic daily administration for 30 days starting on day 30 of tumor growth produced an increase in OVCAR-5 ectopic xenograft ovarian cancer growth in immunocompromised SCID-SHO female mice relative to the vehicle treated group. Symbols represent the means ± SEM. (OVCAR-5 tumor growth in SCID-SHO female mice receiving vehicle, n = 8 SCID-SHO females; OVCAR-5 tumor growth in SCID-SHO female mice receiving JWH-133, n = 8 SCID-SHO females). *p < 0.044 for JWH-133 (1 mg/kg (repeated measures one-way ANOVA).